Trial II of Lung Protection With Azithromycin in the Preterm Infant

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD.

The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hubert Ballard; University of Kentucky
• Collaborator: American Lung Association
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• birthweight less than 1250 grams admitted to UK NICU

• mechanical ventilation within the first 72 hours of life

Exclusion Criteria:

• confirmed sepsis by blood culture

• multiple congenital anomalies or known syndromes

• intrauterine growth retardation with birthweight less than 10%ile for gestational age

• ROM for >7 days